Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia

Timing of response to venetoclax combination treatment in older patients with acute myeloid leuk...Подробнее

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AMLПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее

Current research in elderly, untreated AML: venetoclax combinationsПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Promising results for venetoclax combination therapies in elderly AMLПодробнее

Brian Jonas, MD, Discusses FDA Approval of Venclexta® for the Treatment of Newly Diagnosed AML.Подробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Venetoclax, CLAD/LDAC and azacitdine in older AML patientsПодробнее

Idasanutlin and venetoclax in elderly R/R AMLПодробнее

Venetoclax Combination Therapy and Elderly AML PatientsПодробнее

Targeting BCL-2 in older AML: novel venetoclax combinationsПодробнее

Venetoclax combinations effective in elderly AMLПодробнее

Pivekimab sunirine in combination with venetoclax and azacitidine for CD123-positive AMLПодробнее

Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapyПодробнее

Novel approaches to treating AML in elderly patientsПодробнее

Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)Подробнее

HMA in combination with venetoclax and magrolimab in the treatment of AMLПодробнее